These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22873627)

  • 1. Closing remarks.
    Kudo M
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():52. PubMed ID: 22873627
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib-induced hepatic encephalopathy.
    Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
    Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
    Duan F; Wang MQ; Liu FY; Wang ZJ; Song P; Wang Y
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):156-63. PubMed ID: 22524574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.
    Subramanian M; Singal AG; Yopp AC
    Clin Gastroenterol Hepatol; 2012 Oct; 10(10):e83-4. PubMed ID: 22813441
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
    Nishiofuku H; Tanaka T; Anai H; Sueyoshi S; Maeda S; Masada T; Kichikawa K
    Anticancer Res; 2012 Sep; 32(9):4121-4. PubMed ID: 22993371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
    Lencioni R
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
    O'Neil BH; Venook AP
    Oncologist; 2007 Dec; 12(12):1425-32. PubMed ID: 18165619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
    Chan SL; Johnson P
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):111-4. PubMed ID: 22524569
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hepatocellular carcinoma management in the era of sorafenib].
    Rosmorduc O
    Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
    [No Abstract]   [Full Text] [Related]  

  • 10. [The treatment of hepatocellular carcinoma. New developments].
    Kuiken SD; van Delden OM; Richel DJ; Jansen PL
    Ned Tijdschr Geneeskd; 2009 Apr; 153(14):668-72. PubMed ID: 19425326
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib: new indication. For some patients with liver cancer.
    Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
    Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
    Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hepatocellular carcinoma: what's new?].
    Teufel A; Marquardt JU; Galle PR; Wörns M
    Dtsch Med Wochenschr; 2012 Feb; 137(5):210-3. PubMed ID: 22250042
    [No Abstract]   [Full Text] [Related]  

  • 14. Major achievements in hepatocellular carcinoma.
    Bruix J; Llovet JM
    Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA approves sorafenib for patients with inoperable liver cancer.
    Lang L
    Gastroenterology; 2008 Feb; 134(2):379. PubMed ID: 18242200
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up.
    Di Benedetto F; Tarantino G; Montalti R; Ballarin R; D'Amico G; Berretta M; Gerunda GE
    Transpl Int; 2011 Nov; 24(11):e97; author reply e98-9. PubMed ID: 21910763
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
    Dufour JF; Hoppe H; Heim MH; Helbling B; Maurhofer O; Szucs-Farkas Z; Kickuth R; Borner M; Candinas D; Saar B
    Oncologist; 2010; 15(11):1198-204. PubMed ID: 21036880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.